Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective study with Multicenter to compare the efficacy of Desmopressin alone and Imidafenacin combined treatment for symptom improvement in patients with nocturia with irritable bladder symptoms

Next Previous
Trial Profile

Prospective study with Multicenter to compare the efficacy of Desmopressin alone and Imidafenacin combined treatment for symptom improvement in patients with nocturia with irritable bladder symptoms

Status: Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Oct 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Desmopressin (Primary) ; Imidafenacin (Primary) ; Tamsulosin
  • Indications Nocturia; Overactive bladder
  • Focus Therapeutic Use
  • Acronyms PMDI

Most Recent Events

  • 03 Oct 2019 Planned End Date changed to 31 May 2020.
  • 03 Oct 2019 Planned primary completion date changed to 31 Dec 2019.
  • 23 Sep 2019 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top